Is Breyna Safe in Pregnancy?
Yes, Breyna (budesonide/formoterol) can be safely used during pregnancy, with budesonide being the preferred inhaled corticosteroid and formoterol having a safety profile similar to albuterol, which has reassuring pregnancy data. The critical principle is that uncontrolled asthma poses a definite risk to both mother and fetus, making treatment essential 1, 2.
Evidence Supporting Safety
Budesonide Component - Strong Safety Data
The budesonide component of Breyna has the most robust pregnancy safety evidence of all inhaled corticosteroids:
Large Swedish registry data covering 2,968 pregnant women exposed to inhaled budesonide showed no increased risk of congenital malformations (3.8% vs. 3.5% in general population), normal gestational age, birth weight, and length 2, 3
Orofacial clefts specifically examined: 4 cases observed versus 3.3 expected in normal population - no increased risk 2
Budesonide is the only inhaled corticosteroid designated as Pregnancy Category B (now considered compatible), while all other inhaled corticosteroids are Category C 2, 4
NAEPP guidelines explicitly state budesonide is the preferred inhaled corticosteroid because more pregnancy data exists for it than any other inhaled corticosteroid, and the data are reassuring 1
Formoterol Component - Acceptable Safety Profile
The formoterol component has less direct pregnancy data but acceptable safety:
Pharmacologic profile similar to short-acting beta-agonists like albuterol, which has extensive reassuring pregnancy data 1
No teratogenic effects in rats at inhaled doses up to 375 times the maximum recommended human dose 2
The 2020 ERS/TSANZ guidelines classify formoterol as "probably safe" with the caveat that if a woman was already controlled on formoterol pre-pregnancy, continuing is acceptable 5
Clinical Decision Algorithm
If Patient Already on Breyna Pre-Pregnancy:
Continue the medication - Switching formulations may jeopardize asthma control, which poses greater risk than continuing 1
If Starting New Therapy During Pregnancy:
Breyna is an appropriate choice for moderate persistent asthma requiring combination therapy, as:
- Budesonide is the preferred inhaled corticosteroid 1
- The combination approach is supported for moderate-to-severe asthma 1
Monitoring Requirements:
- Close asthma control monitoring throughout pregnancy
- Serial ultrasounds starting at 32 weeks for suboptimally controlled asthma 1
- Attention to fetal activity 1
Critical Caveats
Risk of Uncontrolled Asthma Exceeds Medication Risk
The most important consideration: poorly controlled asthma during pregnancy increases risk of:
- Preeclampsia in the mother
- Prematurity, low birth weight, and small-for-gestational-age infants
- Severe exacerbations that can cause fetal problems 2
This risk definitively outweighs any theoretical medication concerns 1.
Labor and Delivery Consideration
Use during labor should be restricted to patients where benefits clearly outweigh risks, as beta-agonists can potentially interfere with uterine contractility 2. However, this is a theoretical concern and should not prevent use earlier in pregnancy.
Animal Data Context
While animal studies showed some adverse effects at high doses (umbilical hernias, reduced fetal weight), these occurred at doses exceeding human exposure and rodents are more prone to corticosteroid teratogenic effects than humans 2. The human data is reassuring and takes precedence.
Practical Implementation
Do not discontinue or avoid Breyna due to pregnancy concerns. The evidence strongly supports that maintaining asthma control with budesonide/formoterol is safer than risking exacerbations from undertreated asthma. The extensive Swedish registry data on budesonide (over 6,600 exposed pregnancies across multiple studies) provides robust reassurance 4, 3.
If the patient expresses concern, emphasize that budesonide has more pregnancy safety data than any other inhaled corticosteroid, and that the combination with formoterol follows established guidelines for moderate-to-severe asthma management during pregnancy 1, 5.